Mannatech (NASDAQ:MTEX – Get Free Report) and Enlivex Therapeutics (NASDAQ:ENLV – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, analyst recommendations, dividends, earnings and institutional ownership.
Risk and Volatility
Mannatech has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Mannatech and Enlivex Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mannatech | 1 | 0 | 0 | 0 | 1.00 |
| Enlivex Therapeutics | 1 | 1 | 1 | 1 | 2.50 |
Insider & Institutional Ownership
13.0% of Mannatech shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 47.5% of Mannatech shares are owned by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Mannatech and Enlivex Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Mannatech | $108.04 million | 0.08 | -$15.21 million | ($6.71) | -0.69 |
| Enlivex Therapeutics | N/A | N/A | $1.24 billion | ($8.25) | -0.27 |
Enlivex Therapeutics has lower revenue, but higher earnings than Mannatech. Mannatech is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Mannatech and Enlivex Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mannatech | -11.97% | -2,383.34% | -40.24% |
| Enlivex Therapeutics | N/A | 248.08% | 206.39% |
Summary
Enlivex Therapeutics beats Mannatech on 10 of the 14 factors compared between the two stocks.
About Mannatech
Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.
About Enlivex Therapeutics
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Receive News & Ratings for Mannatech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mannatech and related companies with MarketBeat.com's FREE daily email newsletter.
